A pill for HIV prevention: Déjà vu all over again?

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1604-1612

  Myers, Julie E ^a,b   Sepkowitz, Kent A ^c  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b Department of Medicine   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

birth control; historical insight; HIV prevention; oral contraceptives; pre exposure prophylaxis

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETYNODREL; PLACEBO; TENOFOVIR;

ANTIVIRAL RESISTANCE; BIRTH CONTROL; BONE DENSITY; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; THROMBOEMBOLISM;

BIRTH CONTROL; HISTORICAL INSIGHT; HIV PREVENTION; ORAL CONTRACEPTIVES; PRE-EXPOSURE PROPHYLAXIS;

ANTI-HIV AGENTS; ANTIBIOTIC PROPHYLAXIS; CLINICAL TRIALS AS TOPIC; CONTRACEPTIVES, ORAL; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84877285820     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit085     Document Type: Review

References (60)

1. Food and Drug Administration (FDA). FDA approves first drug for reducing the risk of sexually acquired HIV infection [press release]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnou ncements/ucm312210.htm. Accessed 19 August 2012.
2. Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health 2011; 101:982-85.
3. Tyrer L. Introduction of the pill and its impact. Contraception 1999; 59(1 Suppl):11S-16S.
4. Watkins ES. On the pill: a social history of oral contraceptives, 1950-1970. Baltimore, Maryland: Johns Hopkins University Press, 1998
5. PBS: American Experience. Timeline: The Pill. Available at: http://www.pbs.org/wgbh/amex/pill/timeline/timeline2.html. Accessed 19 August 2012.
6. Asbell B. The pill: a biography of the drug that changed the world. New York, NY: Random House, 1995.
7. Cohen J. AIDS research: new drug shows promise in monkeys. Science 1995; 270:1121-22.
8. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197-99.
9. Singh JA, Mills EJ. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med 2005; 2:e234.
10. Myers JE, Rucinski K, Mensah N, Sepkowitz KA, Cutler B, Sweeney M. Knowledge and use of pre-exposure prophylaxis (PrEP) among young men who have sex with men (MSM) in New York City. In: Results of an Online Survey International AIDS Conference. Washington, DC, 2012.
11. Kapur A, Tang E, Tieu H-V, Koblin B, Ellman T, Sobieszczyk M. Knowledge, attitudes, and willingness of New York City (NYC) providers to prescribe oral pre-exposure Prophylaxis (PrEP) for HIV prevention [Poster WEPE273]. In: XIX International AIDS Conference. Washington, DC, 2012.
12. Kellerman SE, Hutchinson AB, Begley EB, Boyett BC, Clark HA, Sullivan P. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr 2006; 43:376-77.
13. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophy-laxis for HIV prevention in men who have sex with men. The New England Journal of Medicine 2010; 363:2587-99.
14. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New Engl J Med 2012; 367:399-410.
15. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preex-posure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med 2012; 367:423-34.
16. Brody JE. The Pill: Revolution in Birth Control. New York Times 1966; Sect. p. 1, p. 34.
17. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thrombo-embolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969; 90:365-80.
18. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical guidelines for the protection of human subjects of research. Washington, DC: Department of Health, Education, and Welfare, 1978.
19. Gilead. Truvada for pre-exposure prophylaxis of HIV-1. In: Antiviral Drugs Advisory Committee Meeting Briefing Document, 2012.
20. Aaron E, Cohan D. Pre-exposure prophylaxis for the prevention of HIV transmission to women in the United States. AIDS 2013; 27:F1-5.
21. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. New Engl J Med 2012; 367:411-22.
22. Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med 2008; 16:122-6.
23. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PloS One 2011; 6:e23688.
24. Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception 2012; 86:606-21.
25. Antiviral Drugs Advisory Committee (ADVAC). Transcript of the May 10, 2012 meeting. Silver Spring, MD, 2012.
26. French National Agency for Research on AIDS and Viral Hepatitis (ANRS). Intervention Preventive de l'Exposition aux Risques avec et pour les Gays (IPERGAY). Available at: http://www.ipergay.fr/. Accessed 30 September 2012.
27. HIV Prevention Trials Network (HPTN). HPTN 067 (The ADAPT Study): A Phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). Available at
28. http://www.hptn.org/research-studies/hptn067.asp. Accessed 30 September 2012.
29. Microbicide Trials Network (MTN). MTN-007: A Phase I study designed to determine if rectal use of a reformulated version of tenofovir gel is safe and whether men and women would be willing to use it as a rectal microbicide. Available at: http://www.mtnstopshiv.org/news/studies/mtn007. Accessed 30 September 2012.
30. Schmeck HM Jr. Birth-Curb Group to Distribute Pill. New York Times. 1960.
31. CoinNews Media Group LLC. US Inflation Calculator. Available at: http://www.usinflationcalculator.com/. Accessed 19 August 2012.
32. May ET. America and the Pill: A History of Promise, Peril, and Liberation. New York, NY: Basic Books, 2010.
33. Horberg M, Raymond B. Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance. Am J Preventive Med 2013; 44(1 Suppl 2):S125-28.
34. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-97.
35. Jay JS, Gostin LO. Ethical challenges of preexposure prophylaxis for HIV. JAMA. 2012; 308(9):867-8.
36. Doob G. In 1965, Brown physician sparked furor over the Pill. The Brown Daily Herald. Providence, Rhode Island, 2007.
37. iPrEx Open Label Extension (OLE). Available at: http://www.iprexole. com/. Accessed 24 September 2012.
38. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51:283-88.
39. Auerbach JD, Banyan A, Riordan M. Will and should women in the U.S. use PrEP? Findings from a focus group study of at-risk, HIV-negative women. In: XIX International AIDS Conference Washington. Oakland, Memphis, San Diego and Washington, DC, 2012.
40. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preex-posure prophylaxis among potential user groups: a multinational study. PloS One 2012; 7:e28238.
41. Holt M, Murphy DA, Callander D, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Trans Inf 2012; 88:258-63.
42. Zhou F, Gao L, Li S, et al. Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PloS One 2012; 7:e32329.
43. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS 2012; 26:87-94.
44. Leonardi M, Lee E, Tan DH. Awareness of, usage of and willingness to use HIV pre-exposure prophylaxis among men in downtown Toronto, Canada. Int J STD and AIDS 2011; 22:738-41.
45. Heffron R, Ngure K, Mugo N, et al. Willingness of Kenyan HIV-1 Serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies. J Acquir Immune Defic Syndr 2012; 61:116-9.
46. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PloS One 2012; 7:e40603.
47. Van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-19.
48. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 2012; 59:463-68.
49. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008; 77:1-5.
50. Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies. Am J Prevent Med 2013; 44(1 Suppl 2): S91-S98.
51. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4:151ra125.
52. Mansergh G, Koblin BA, Sullivan PS. Challenges for HIV pre-exposure prophylaxis among men who have sex with men in the United States. PLoS Med 2012; 9:e1001286.
53. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 2010; 54:548-55.
54. Schnell D, Zaidi A, Reynolds G. A time series analysis of gonorrhea surveillance data. Stat Med 1989; 8:343-52; discussion 63.
55. Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PloS One 2011; 6: e18165.
56. McKinnell JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naive patients in the United States. AIDS Patient Care STDS 2010; 24:79-85.
57. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Stat 2010; 23:1-44.
58. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep 2010; 7:201-9.
59. HIV Prevention Trials Network (HPTN). HPTN 069: Phase II randomized, double-blind, study of safety and tolerability of maravir-oc, maraviroc + emtricitabine, maraviroc + tenofovir or tenofovir + emtricitabine for preexposure prophylaxis to prevent HIV transmission in at-risk men who have sex with men. Available at: http://www. hptn.org/research-studies/hptn069.asp. Accessed 30 September 2012.
60. Microbicide Trials Network (MTN). VOICE (vaginal and oral interventions to control the epidemic)-003. Available at: www.mtnstopshiv. org/news/studies/mtn003. Accessed 20 January 2013.